Post-thrombotic syndrome prevention on patients after COVID-19

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/3972

Full metadata record

DC Field	Value	Language
dc.contributor.author	Akmal Irnazarov, Uktamkhon Asrarov, Jakhongir Matmuradov	-
dc.date.accessioned	2022-10-13T07:04:27Z	-
dc.date.available	2022-10-13T07:04:27Z	-
dc.date.issued	2022-09-12	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/3972	-
dc.description.abstract	There were 64 male gender patients from December 2020 until July 202l in Multidisciplinary clinic of Tashkent Medical Academy with acute iliofemoral venous thrombosis, which were divided into 2 groups. All patients had had coronavirus infection 2-2.5 months before hospitalization. Main group included 29 patients, whom peroral anticoagulant had been carried out in the next scheme: Rivaroxaban 40 mg qDay l st week, then Rivaroxaban 30 mg q Day for 2 weeks and Rivaroxaban 20 mg qDay for 3 months. Control group had taken standard scheme of therapy.	en_US
dc.language.iso	en	en_US
dc.publisher	Turkey	en_US
dc.subject	Arterial and venous thromboses are most frequent complications after COVID-19. According to JAMA Open Network, on 2/3 patients after coronavirus infection developed arterial and venous thromboses. Rupin Aria discovers thrombotic events on 70% after coronavirus infection despite taking antiplatelet therapy.	en_US
dc.title	Post-thrombotic syndrome prevention on patients after COVID-19	en_US
dc.type	Thesis	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
6.pdf	Post-thrombotic syndrome prevention on patients after COVID-19	46.1 kB	Adobe PDF	View/Open

DSpace JSPUI